{
  "docId": "019de070-699f-77f8-bbbb-b770da56fde3",
  "docSlug": "068a25e0403b2abb3acbdc102f073cd6",
  "documentTitle": "BioNTech | Results Presentation Deck | 25 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 25,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "other",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 60,
  "notes": "Waterfall plot showing clinical trial efficacy data.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-699f-77f8-bbbb-b770da56fde3/19",
  "deckHref": "/decks/019de070-699f-77f8-bbbb-b770da56fde3",
  "deckJsonHref": "/decks/019de070-699f-77f8-bbbb-b770da56fde3.json",
  "deckAnchorHref": "/decks/019de070-699f-77f8-bbbb-b770da56fde3#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.7
      },
      "kind": "callout",
      "text": "Disease control achieved in 65.6% of patients; four patients with PR. Includes 4 early partial responses in TNBC (1), ovarian cancer (1), and ICI-pre treated NSCLC (2) patients",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e09284d5-9e59-4064-8b79-bb31bf46e257",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.92,
        "x": 0.04,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Best percent change from baseline in tumor size",
      "attrs": null,
      "subkind": "waterfall",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ae6e3f3-797a-4503-ab82-a5c7eafb8da2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.08,
        "y": 0.86
      },
      "kind": "source-note",
      "text": "Data cut-off: September 29, 2020. Post-baseline scans were not conducted for five patients. aMinimum duration of response (5 weeks) per RECIST v1.1 not reached. bPR was not confirmed on a subsequent scan. NE, non-evaluable; NSCLC, non-small cell lung cancer; PD, progressive disease; PD-(L)1, programmed death (ligand) 1; PR, partial response; SD, stable disease; SoD, sum of diameters; uPR, unconfirmed partial response.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c421267e-4f3e-49f1-85a3-5ff2b98e97bd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.75,
        "x": 0.04,
        "y": 0.09
      },
      "kind": "title",
      "text": "BNT311: Phase 1 / 2a - Anti-tumor Activity: Dose escalation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40cbcf02-8f37-4ddf-bf48-33586731616a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "05a1e16e-ef32-40db-8c18-aab89093ec6e",
      "evidence": "The slide features a waterfall chart titled 'Best percent change from baseline in tumor size', which directly instantiates the waterfall chart tool.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 7,
      "beatId": "7852d973-8bf2-4ccc-98c8-69a7695d2975",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "BNT162b2 Phase 3 trial, oncology pipeline, and BNT311 safety trial",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}